Rosetta Amends IPO Terms

Rosetta Genomics Ltd., an Israel-based drug company focused on microRNAs, has amdned its IPO terms to 3.75 million ordinary shares being offered at between $7.50 and $8.50 per share. It previously filed to sell 3 million shares at between $11 and $13 per share. It still plans to trade on the Nasdaq under ticker symbol RSOG, with C.E. Unterberg Towbin serving as lead underwriter. Backers include Insight Capital and Kadima Hi-Tech Ltd.< ?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />